SONN Overview

Sonnet BioTherapeutics Holdings, Inc. is a clinical-stage, oncology-focused biotechnology company with a proprietary platform for biologic medicines of single-or bifunctional action. The Fully Human Albumin Binding (FHAB), a technology which utilizes a fully human single chain antibody fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its FHAB is designed to specifically target tumor and lymphatic tissue. The Company's lead program, SON-1010, or IL-12-FHAB, is in development for the treatment of solid tumors and ovarian cancer. SON-1010 is being evaluated in an ongoing Phase 1/2a study, in combination with atezolizumab (Tecentriq) for the treatment of platinum-resistant ovarian cancer (PROC). The Company is also evaluating its second program, SON-1210, an IL12-FHAB-IL15 for solid tumor. Its SON-080 program is a low dose of rhIL-6 in development for Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN).

Wall Street analysts forecast SONN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SONN is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Sonnet Biotherapeutics Holdings Inc revenue for the last quarter amounts to 0.00 USD, decreased

Sonnet Biotherapeutics Holdings Inc. EPS for the last quarter amounts to USD, decreased -100.00

Sonnet Biotherapeutics Holdings Inc (SONN) has 13 emplpoyees as of March 28 2026.

Today SONN has the market capitalization of 2.95M USD.